Last week, BUR reported H1 22 results. The most important takeaway is that the company is cash break-even and tangible book value per share (TBVPS) didn’t change.
This is mainly because cash realizations were slow; BUR is still seeing delays in case progression due to the backlog in courts from COVID. We recently discussed in more detail about BUR's lack of TBVPS growth over the last few years.
Although BUR-only commitments grew 4% YoY to $295m, a H1 record, deployments were down YoY to $128m. If we exclude the huge $138m deployment in H1 21 with the BOFC sidecar, ‘normal’ sized capital provision deployments actually grew in H1 22. However, we believe such outsized deals are now a regular part of BUR’s business and should be included in any YoY comparison.
Both deployment and realisations are slow. But management have always warned investors of this: they don’t know how or when cases will realise. And they likely won’t ever truly know. Because if they did, the beauty of capital markets would mean BUR wouldn’t be able to earn the underlying case ROI that it does today. BUR CEO warned us of this on the earnings call:
There are too many idiosyncratic variables in the mix beyond just understanding generally how long it takes for cases to get through courts. And so, it is not something that we believe that we can do with the kind of accuracy and reliability that we would be comfortable doing publicly. I would say, would that we could. But on the other hand, if this business were entirely predictable as to both duration and outcome, then we would not be able to generate the returns that we can, I think, is the countervailing factor. - Burford Capital CEO, H1 22 Earnings
In fact, even if BUR did understand the duration of cases, would it be wise to communicate this publicly? Competitors could better assess the risk of litigation assets and arbitrage BUR’s return. Investors would also plug the duration into DCF’s so precisely that BUR would become closer to a bank than a specialty litigation financier.
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities.
© 2023 IP 1 Ltd. All rights reserved.
Subscribe to access hundreds of interviews and primary research